Gilead Sciences Revenue 2010-2022 | GILD

Gilead Sciences annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Gilead Sciences revenue for the quarter ending September 30, 2022 was $7.042B, a 5.11% decline year-over-year.
  • Gilead Sciences revenue for the twelve months ending September 30, 2022 was $27.136B, a 1.26% decline year-over-year.
  • Gilead Sciences annual revenue for 2021 was $27.305B, a 10.6% increase from 2020.
  • Gilead Sciences annual revenue for 2020 was $24.689B, a 9.98% increase from 2019.
  • Gilead Sciences annual revenue for 2019 was $22.449B, a 1.46% increase from 2018.
Gilead Sciences Annual Revenue
(Millions of US $)
2021 $27,305
2020 $24,689
2019 $22,449
2018 $22,127
2017 $26,107
2016 $30,390
2015 $32,639
2014 $24,890
2013 $11,202
2012 $9,702
2011 $8,385
2010 $7,949
2009 $7,011
Gilead Sciences Quarterly Revenue
(Millions of US $)
2022-09-30 $7,042
2022-06-30 $6,260
2022-03-31 $6,590
2021-12-31 $7,244
2021-09-30 $7,421
2021-06-30 $6,217
2021-03-31 $6,423
2020-12-31 $7,421
2020-09-30 $6,577
2020-06-30 $5,143
2020-03-31 $5,548
2019-12-31 $5,879
2019-09-30 $5,604
2019-06-30 $5,685
2019-03-31 $5,281
2018-12-31 $5,795
2018-09-30 $5,596
2018-06-30 $5,648
2018-03-31 $5,088
2017-12-31 $5,949
2017-09-30 $6,512
2017-06-30 $7,141
2017-03-31 $6,505
2016-12-31 $7,320
2016-09-30 $7,500
2016-06-30 $7,776
2016-03-31 $7,794
2015-12-31 $8,506
2015-09-30 $8,295
2015-06-30 $8,244
2015-03-31 $7,594
2014-12-31 $7,314
2014-09-30 $6,042
2014-06-30 $6,535
2014-03-31 $4,999
2013-12-31 $3,120
2013-09-30 $2,783
2013-06-30 $2,767
2013-03-31 $2,532
2012-12-31 $2,588
2012-09-30 $2,427
2012-06-30 $2,405
2012-03-31 $2,282
2011-12-31 $2,200
2011-09-30 $2,122
2011-06-30 $2,137
2011-03-31 $1,926
2010-12-31 $1,999
2010-09-30 $1,938
2010-06-30 $1,927
2010-03-31 $2,086
2009-12-31 $2,032
2009-09-30 $1,801
2009-06-30 $1,647
2009-03-31 $1,530
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $105.984B $27.281B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00